Biocryst Pharmaceuticals Inc.’s filing revealed that its Director McKee Amy E unloaded Company’s shares for reported $54352.0 on Jun 24 ’24. In the deal valued at $6.32 per share,8,600 shares were sold. As a result of this transaction, McKee Amy E now holds 27,831 shares worth roughly $0.21 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, SANDERS MACHELLE sold 4,689 shares, generating $28,134 in total proceeds. Upon selling the shares at $6.00, the Director now owns 27,742 shares.
Before that, HEGGIE THERESA sold 6,698 shares. Biocryst Pharmaceuticals Inc. shares valued at $40,925 were divested by the Director at a price of $6.11 per share. As a result of the transaction, HEGGIE THERESA now holds 52,852 shares, worth roughly $0.4 million.
A number of analysts have revised their coverage, including RBC Capital Mkts’s analysts, who increased its forecast for the stock in mid September from “a Sector perform” to “an Outperform”. Jefferies also remained covering BCRX and has increased its forecast on August 04, 2023 with a “Buy” recommendation from previously “Hold” rating. BofA Securities revised its rating on July 13, 2023. It rated BCRX as “a Buy” which previously was an “a Neutral”.
Price Performance Review of BCRX
On Friday, Biocryst Pharmaceuticals Inc. [NASDAQ:BCRX] saw its stock jump 2.16% to $7.58. Over the last five days, the stock has lost -0.52%. Biocryst Pharmaceuticals Inc. shares have risen nearly 26.54% since the year began. Nevertheless, the stocks have risen 21.28% over the past one year. While a 52-week high of $8.88 was reached on 09/03/24, a 52-week low of $4.03 was recorded on 04/25/24. SMA at 50 days reached $7.81, while 200 days put it at $6.27.
Levels Of Support And Resistance For BCRX Stock
The 24-hour chart illustrates a support level at 7.47, which if violated will result in even more drops to 7.36. On the upside, there is a resistance level at 7.66. A further resistance level may holdings at 7.74. The Relative Strength Index (RSI) on the 14-day chart is 45.17, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.23, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 67.92%. Stochastics %K at 20.75% indicates the stock is a holding.
How much short interest is there in Biocryst Pharmaceuticals Inc.?
A steep rise in short interest was recorded in Biocryst Pharmaceuticals Inc. stocks on 2024-09-13, dropping by -0.49 million shares to a total of 24.32 million shares. Yahoo Finance data shows the prior-month short interest on 2024-08-15 was 24.81 million shares. There was a decline of -2.0%, which implies that there is a negative sentiment for the stock.
